Search results for "Drug administration"

showing 10 items of 393 documents

Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants

2007

Objectives Because young infants are at highest risk of pertussis complications, this study assessed whether neonatal acellular pertussis (aP) vaccination could provide earlier immunity. Study design Neonates (n = 121) were randomly assigned (1:1) to receive either aP or hepatitis B vaccine (HBV) (controls) vaccine at birth, followed by vaccination with DTaP-HBV-IPV/Hib at 2, 4 and 6 months. Immune responses were measured. Reactogenicity was assessed for 7 days after each dose. Results The aP birth dose was followed by few adverse events. Reactogenicity of subsequent vaccine doses did not differ between groups. Seven serious adverse events were reported from each group; none were related to…

MaleHBsAgHepatitis B vaccineTime Factorsddc:616.07Bordetella pertussisDrug Administration ScheduleVaccines AcellularDouble-Blind MethodmedicineHumansWhooping coughPertussis VaccineVaccines Acellular/administration & dosageReactogenicityTetanusbusiness.industryDiphtheriaAge FactorsInfant NewbornInfantAntibodies Bacterial/bloodmedicine.diseasePertussis Vaccine/administration & dosageAntibodies BacterialVaccinationImmunoglobulin G/bloodImmunoglobulin GPediatrics Perinatology and Child HealthImmunologyFeasibility StudiesFemalePertactinbusinessBordetella pertussis/immunologyFollow-Up Studies
researchProduct

Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.

2019

ObjectivesBimatoprost–timolol (bimatoprost 0.03%–timolol 0.5% fixed-dose combination [FDC]) and tafluprost–timolol (tafluprost 0.0015%–timolol 0.5% FDC) eye drops are currently the only topical intraocular pressure (IOP)-reducing therapies available as preservative-free (PF) prostaglandin and timolol FDC. The aim of this study was to investigate changes to ocular signs and symptoms when patients with ocular hypertension (OH) or open-angle glaucoma (OAG) switched from PF or benzalkonium chloride (BAK)-preserved bimatoprost–timolol to PF tafluprost–timolol eye drops.DesignThis was a 12-week, open-label, phase IV study.SettingSixteen centres in Finland, Germany, Italy and the UK.ParticipantsPa…

MaleIntraocular pressuregenetic structuresOcular hypertensionGlaucomaTimololBenzalkonium chloride0302 clinical medicine1506clinical pharmacology; clinical trials; glaucoma; intraocular pressure; medical ophthalmology; ocular surface; Medicine (all)Aged 80 and overintegumentary systemMedicine (all)General MedicineMiddle AgedIntention to Treat AnalysisDrug Combinations030220 oncology & carcinogenesisTimololFemaleGlaucoma Open-Anglemedicine.drug1718Adultmedicine.medical_specialtyDrug Administration Schedule03 medical and health sciencesOphthalmologymedicineHumansAntihypertensive AgentsIntraocular PressureAgedclinical trialsocular surfaceBimatoprostbusiness.industryResearchPreservatives PharmaceuticalProstaglandins FTafluprostmedicine.diseaseeye diseasesmedical ophthalmologyClinical trialOphthalmologyBimatoprostglaucoma030221 ophthalmology & optometryQuality of LifeOcular Hypertensionsense organsclinical pharmacologyOphthalmic SolutionsbusinessBMJ open
researchProduct

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

2013

International audience; BACKGROUND: The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo. METHODS: We randomly assigned patients 40 years of age or older who were hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg onc…

MaleMESH: Factor Xa[SDV]Life Sciences [q-bio]Administration Oral030204 cardiovascular system & hematologylaw.inventionMESH: Venous Thromboembolismchemistry.chemical_compound0302 clinical medicineRivaroxabanRandomized controlled triallawMedicineMESH: Double-Blind Method030212 general & internal medicineMESH: AgedMESH: Middle AgedVenous ThromboembolismGeneral MedicineMiddle AgedMESH: Thiophenes3. Good healthAnesthesiaAcute DiseaseMESH: Administration OralMESH: Acute DiseaseFemaleMESH: Hemorrhagemedicine.drugAdultRandomizationMESH: EnoxaparinInjections SubcutaneousMorpholinesMESH: MorpholinesHemorrhageThiophenesMESH: AnticoagulantsMESH: Drug Administration SchedulePlaceboDrug Administration Schedule03 medical and health sciencesDouble-Blind MethodRivaroxaban venous thromboembolismHumansEnoxaparinAgedRivaroxabanMESH: Humansbusiness.industryMESH: Injections SubcutaneousAnticoagulantsMESH: AdultConfidence intervalMESH: MalechemistryBetrixabanRelative riskbusinessVenous thromboembolismMESH: FemaleFactor Xa Inhibitors
researchProduct

Clozapine: Strong antiaggressive effects with minimal motor impairment

1992

Abstract Clinical studies have shown clozapine to be effective in the treatment of schizophrenia and associated with an extremely low incidence of extrapiramidal side effects. Diverse studies indicate that clozapine is an atypical neuroleptic with a preferential activity on the mesolimbic structures and a lower affinity for striatal D2 receptors than the classical antipsychotics. The purpose of this study was to assess the behavioral properties of clozapine, especially its effects on aggressive and motor behaviors. Individually housed male mice of the OF1 strain were exposed to anosmic “standard opponents” 30 minutes after the last drug administration. One category of animals received a sin…

MaleMale miceExperimental and Cognitive PsychologyAtypical neurolepticMotor ActivityPharmacologyMiceBehavioral NeuroscienceDopamine receptor D2medicineAnimalsClozapineClozapineDose-Response Relationship DrugDrug administrationMotor impairmentmedicine.diseaseAggressionLower affinityMotor SkillsSchizophreniaAnesthesiaArousalPsychologyPsychomotor Performancemedicine.drugPhysiology & Behavior
researchProduct

Antiaggressive and motor effects of haloperidol show different temporal patterns in the development of tolerance.

1993

Abstract The study of the temporal course of tolerance development was used as a means to separate different aspects of the action of haloperidol on social behavior. Agonistic behavior was studied in isolated male mice that confronted standard opponents (anosmic and grouped conspecifics) in a neutral area. The aggressive and motor behaviors of the experimental animals were evaluated 30 min or 24 h either after a single injection of haloperidol (0.4 mg/kg) or following the last of a series of 15 or 30 injections. When animals were evaluated 30 min after the haloperidol injection, no tolerance to the antiaggressive effects was evident. The action on immobility, on the contrary, showed a clear…

MaleMale miceExperimental and Cognitive PsychologyPharmacologyMotor ActivityDrug Administration ScheduleBehavioral NeuroscienceMiceNeural PathwaysAgonistic behaviourHaloperidolmedicineAnimalsDose-Response Relationship DrugDrug administrationBrainSingle injectionHaloperidol injectionBehavioral analysisAggressionHaloperidolPsychologyArousalNeuroscienceAgonistic Behaviormedicine.drugPhysiologybehavior
researchProduct

Clarithromycin Versus Azithromycin in the Treatment of Mediterranean Spotted Fever in Children: A Randomized Controlled Trial

2002

We conducted an open-label randomized controlled trial to compare the efficacy and safety of clarithromycin (15/mg/kg/day in 2 divided doses for 7 days) with those of azithromycin (10 mg/kg/day in 1 dose for 3 days) in the treatment of children with Mediterranean spotted fever. Until now, there has not been a gold-standard therapy for this rickettsial disease in children. Eighty-seven children were randomized to receive 1 of the 2 drugs. The mean time to defervescence (+/- standard deviation) was 46.2+/-36.4 h in the clarithromycin group and 39.3+/-31.3 h in the azithromycin group. These differences were not statistically significant and both drugs were equally well-tolerated. Clarithromyci…

MaleMicrobiology (medical)medicine.medical_specialtyAdolescentErythromycinAzithromycinBoutonneuse FeverAzithromycinDrug Administration Schedulelaw.inventionRandomized controlled triallawClarithromycinClarithromycinInternal medicinemedicineHumansChildAntibacterial agentMediterranean spotted fever Clarithromycin azithromycinbusiness.industryInfantmedicine.diseaseAnti-Bacterial AgentsSurgerySpotted feverBoutonneuse feverRickettsia conoriiTreatment OutcomeInfectious DiseasesRickettsiosisChild PreschoolFemalebusinessmedicine.drugClinical Infectious Diseases
researchProduct

Inhibition of myosin light chain kinase reduces brain edema formation after traumatic brain injury.

2010

The role of the endothelial contractile apparatus in the process of brain edema formation after brain trauma is not characterized. Phosphorylation of myosin light chains by myosin light chain kinases (MLCK) activates endothelial contractile elements and results in a rearrangement of the cytoskeleton. This may enhance post-traumatic blood-brain barrier dysfunction. In order to investigate the role of the MLCK on brain edema formation and blood-brain barrier permeability after brain injury, mice were anesthetized and subjected to a controlled cortical impact (CCI). MLCK expression is significantly up-regulated after CCI with a maximum 12 h post-injury. Specific inhibition of MLCK by ML-7 resu…

MaleMyosin light-chain kinaseMyosin Light ChainsTime FactorsEndotheliumIntracranial PressureTraumatic brain injuryCentral nervous systemBrain Edemamacromolecular substancesBrain damageNaphthalenesBlood–brain barrierBiochemistryNeuroprotectionDrug Administration ScheduleFunctional LateralityStatistics NonparametricCerebral edemaCellular and Molecular NeuroscienceMicemedicineAnimalsEnzyme InhibitorsMyosin-Light-Chain KinaseNeurologic Examinationbusiness.industryAzepinesmedicine.diseaseConstrictionCell biologyMice Inbred C57BLDisease Models Animalmedicine.anatomical_structureGene Expression RegulationBlood-Brain BarrierBrain Injuriesmedicine.symptombusinessNeuroscienceEvans BlueJournal of neurochemistry
researchProduct

Isolation decreases physical and motivational aspects of morphine withdrawal

2005

Environmental manipulations such as social housing conditions of animals may play a role in the expression of individual differences in response to drugs. This study aimed to evaluate whether isolated and grouped mice develop different degrees of morphine dependence. Isolated and grouped mice were rendered morphine dependent employing two different methods of induction: a fast or slow protocol, both reaching the same maximum daily dose (100 mg/kg). Naloxone-induced morphine withdrawal was assessed using a modified Gellert-Holtzman scale and a conditioned place aversion (CPA) procedure. Isolated animals manifested fewer signs of physical dependence than grouped mice and only those receiving …

MaleNarcoticsmedicine.medical_specialtyEndogenous OpiatesAnalgesicPhysical dependencePharmacologyMiceMorphine withdrawalInternal medicinemedicineAnimalsConditioned place aversionPharmacologyMorphineMorphine dependenceDrug administrationSubstance Withdrawal SyndromePsychiatry and Mental healthEndocrinologySocial IsolationMorphineAnalgesiamedicine.symptomPsychologymedicine.drugBehavioural Pharmacology
researchProduct

MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis

2008

Objective: To prospectively validate MRI activity and neutralising anti-interferon antibody (NAb) during the first 6 months of interferon β treatment as response indicators in multiple sclerosis (MS). Methods: Patients with relapsing–remitting MS were followed during the first 2 years of treatment. Neurological assessments were performed every 3 months or when a relapse was suspected. MRI scans performed at baseline and at 3, 4, 5 and 6 months after the start of treatment were assessed centrally for disease activity: new T2 or gadolinium enhancing T1 lesions. NAb were assessed using the MxA protein assay; positivity was defined as two consecutive titres ⩾20 NU/ml. We evaluated the predictiv…

MaleNeutralising antibodyMULTICENTERPLACEBO-CONTROLLED TRIALGUIDELINESGastroenterologyDOUBLE-BLINDInterferon βMAGNETIC-RESONANCEProspective StudiesNeurologic ExaminationbiologyBrainIMPAIRMENTMiddle AgedPredictive valueMagnetic Resonance ImagingRecombinant ProteinsPsychiatry and Mental healthTreatment OutcomeSettore MED/26 - NeurologiaFemaleAntibodyInterferon beta-1bAdultmedicine.medical_specialtyDIAGNOSTIC-CRITERIAInjections SubcutaneousAntibodiesDrug Administration ScheduleDisease activityMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicNeutralization TestsInternal medicinemedicineHumansInterferon betabusiness.industryMultiple sclerosisDISABILITYMSInterferon-betamedicine.diseaseConfidence intervalSurgerybiology.proteinSurgeryNeurology (clinical)businessFollow-Up Studies
researchProduct

A specific anti-aggressive effect of repeatedly administered lobeline.

2002

The effects of chronic treatments with nicotinic agonists on agonistic encounters have received little attention. The effects of repeated (for 10 days) SC administration of (-)-lobeline (9.3, 18.6 and 37.2 micromol/kg) and (-)-nicotine (0.93, 1.86 and 3.72 micromol/kg) were evaluated using the mouse isolation-induced aggression model. Individually housed OF1 male mice served as experimental animals and were confronted by 'standard opponents'. Each mouse was tested only once on the last day of the repeated drug treatment. Videotaped agonistic encounters were analysed estimating the times allocated to 11 behavioural categories. Repeated treatment with the highest dose of lobeline diminished a…

MaleNicotineMedicine (miscellaneous)Male micePharmacologyMotor ActivityDrug Administration ScheduleNicotinechemistry.chemical_compoundMiceRepeated treatmentAgonistic behaviourmedicineAnimalsLobelineMotor activityNicotinic AgonistsPharmacologyDose-Response Relationship DrugAggressionAggressionPsychiatry and Mental healthNicotinic agonistchemistrySocial IsolationLobelinemedicine.symptomPsychologyAgonistic Behaviormedicine.drugAddiction biology
researchProduct